Financials Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-05-14 am EDT 5-day change 1st Jan Change
5.7 HKD -1.55% Intraday chart for Simcere Pharmaceutical Group Limited -0.18% -15.30%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,011 3,031 3,958 2,255 1,869 - -
Enterprise Value (EV) 2 3,016 2,945 3,796 2,255 1,588 1,501 1,427
P/E ratio 26.9 x 12.6 x 28.5 x 22.7 x 13.6 x 10.6 x 9.17 x
Yield 1.99% 2.05% 1.56% - 2.57% 3.2% 3.61%
Capitalization / Revenue 4.37 x 3.86 x 4.3 x 2.46 x 1.81 x 1.56 x 1.36 x
EV / Revenue 4.38 x 3.75 x 4.13 x 2.46 x 1.54 x 1.25 x 1.04 x
EV / EBITDA 27.9 x 11 x 24 x 17.2 x 8.39 x 6.38 x 5.07 x
EV / FCF - -46.9 x - - 15.3 x 14.4 x 11.3 x
FCF Yield - -2.13% - - 6.53% 6.96% 8.83%
Price to Book 3.4 x 2.97 x 3.83 x - 1.75 x 1.56 x 1.38 x
Nbr of stocks (in thousands) 2,608,642 2,628,291 2,660,377 2,616,723 2,560,985 - -
Reference price 3 7.533 7.325 10.26 6.117 5.277 5.277 5.277
Announcement Date 3/25/21 3/24/22 3/31/23 3/20/24 - - -
1CNY in Million2USD in Million3CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 746.6 688.7 785.2 919.9 917.9 1,033 1,200 1,372
EBITDA 1 - 108 267 158.1 131.1 189.3 235.3 281.1
EBIT 1 - 74.08 178.1 125.6 98.87 139.9 188.2 237.2
Operating Margin - 10.76% 22.68% 13.65% 10.77% 13.55% 15.68% 17.29%
Earnings before Tax (EBT) 1 - 123 220.1 129.3 102.8 143.5 192.5 244.4
Net income 1 148.8 102.3 236.7 135.8 99.28 140.5 179.8 208.7
Net margin 19.93% 14.85% 30.14% 14.76% 10.82% 13.61% 14.98% 15.21%
EPS 2 - 0.2800 0.5800 0.3600 0.2700 0.3888 0.4976 0.5756
Free Cash Flow 1 - - -62.76 - - 103.7 104.5 126
FCF margin - - -7.99% - - 10.04% 8.7% 9.19%
FCF Conversion (EBITDA) - - - - - 54.79% 44.4% 44.83%
FCF Conversion (Net income) - - - - - 73.8% 58.1% 60.4%
Dividend per Share 2 - 0.1500 0.1500 0.1600 - 0.1358 0.1690 0.1904
Announcement Date 10/12/20 3/25/21 3/24/22 3/31/23 3/20/24 - - -
1USD in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1 2023 S2
Net sales 1 - 448.4
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income 312.5 -
Net margin - -
EPS 0.8600 -
Dividend per Share - -
Announcement Date 8/21/23 3/20/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 4.55 - - - - - -
Net Cash position 1 - - 86 162 - 281 367 442
Leverage (Debt/EBITDA) - 0.0421 x - - - - - -
Free Cash Flow 1 - - -62.8 - - 104 104 126
ROE (net income / shareholders' equity) - 19.7% 25.7% 13.8% - 12.4% 14.7% 15.8%
ROA (Net income/ Total Assets) - 7.56% 14.3% 8.91% - 8.39% 10.1% 11.1%
Assets 1 - 1,353 1,657 1,524 - 1,676 1,783 1,877
Book Value Per Share 2 - 2.220 2.470 2.680 - 3.010 3.370 3.830
Cash Flow per Share 2 - 0.0400 -0.0800 0.5200 - 0.2400 0.3900 -
Capex 1 - 54.4 32 49.9 - 84.7 82.5 89
Capex / Sales - 7.9% 4.07% 5.43% - 8.2% 6.87% 6.48%
Announcement Date 10/12/20 3/25/21 3/24/22 3/31/23 3/20/24 - - -
1USD in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.277 CNY
Average target price
7.984 CNY
Spread / Average Target
+51.30%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2096 Stock
  4. Financials Simcere Pharmaceutical Group Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW